1
|
Morisse M, Bourhis T, Lévêque R, Guilbert M, Cicero J, Palma M, Chevalier D, le Bourhis X, Toillon RA, Mouawad F. Influence of EGF and pro-NGF on EGFR/SORTILIN interaction and clinical impact in head and neck squamous cell carcinoma. Front Oncol 2023; 13:661775. [PMID: 37576898 PMCID: PMC10416107 DOI: 10.3389/fonc.2023.661775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Accepted: 07/12/2023] [Indexed: 08/15/2023] Open
Abstract
Head and Neck Squamous Cell Carcinoma (HNSCC) remains a cancer with a poor prognosis, with a 5-year survival rate of less than 50%. Although epidermal growth factor receptor (EGFR) is almost always overexpressed, targeted anti-EGFR therapies have modest efficacy and are mainly used in palliative care. Growth factors such as Nerve Growth Factor (NGF) and its precursor proNGF have been shown in our laboratory to play a role in tumor growth and aggressiveness. Interestingly, an interaction between Sortilin, a proNGF receptor, and EGFR has been observed. This interaction appears to interfere with the pro-oncogenic signaling of EGF and modulate the membrane expression of EGFR. The aim of this study was to characterize this interaction biologically, to assess its impact on clinical prognosis and to analyze its role in the cellular trafficking of EGFR. Using immunohistochemical staining on tumor sections from patients treated at our university center and PLA (Proximity Ligation Assay) labeling, we showed that Sortilin expression is significantly associated with reduced 5-year survival. However, when Sortilin was associated with EGFR, this association was not found. Using the Cal-27 and Cal-33 cancer cell lines, we observed that proNGF reduces the effects of EGF on cell growth by inducing the internalization of its receptor. These results therefore suggest a regulatory role for Sortilin in the degradation or renewal of EGFR on the membrane. It would be interesting in future work to show the intracellular fate of EGFR and the role of (pro)neurotrophins in these mechanisms.
Collapse
Affiliation(s)
- Martin Morisse
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France
- Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Thomas Bourhis
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France
- Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Romain Lévêque
- Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Mathieu Guilbert
- Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Julien Cicero
- Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Martine Palma
- Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Dominique Chevalier
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France
- Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Xuefen le Bourhis
- Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Robert-Alain Toillon
- Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Francois Mouawad
- Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France
- Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| |
Collapse
|
2
|
Vanderhaegen T, Pierache A, Mortuaire G, Rysman B, Nicot R, Chevalier D, Mouawad F. The first wave of COVID-19 did not cause longer wait times in head and neck cancer. Experience of a French expert center. Eur Ann Otorhinolaryngol Head Neck Dis 2022; 139:261-267. [PMID: 35534362 PMCID: PMC9023346 DOI: 10.1016/j.anorl.2022.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Head and neck cancers (HNC) have poor survival prognosis, as tumors are often diagnosed at advanced stages in patients consulting late. The first lockdown linked to the 1st wave of COVID-19 (Coronavirus Disease 2019) disrupted consultation schedules in France. OBJECTIVE The principal aim of the present study was to analyze consultation wait time in HNC during and after lockdown, in our university expert oncology reference center, to disclose any increase in treatment wait time. METHODS A single-center retrospective study included patients with a first diagnosis of HNC. Three groups were distinguished: "lockdown", "post-lockdown", and a "control" group (corresponding to a reference period 1 year earlier). Intervals between first oncologic consultation and multidisciplinary tumor board (FC-MTB) and between MTB and first treatment (MTB-T) were assessed. RESULTS One hundred and seven patients were included in the control group, 60 in the lockdown group and 74 in the post-lockdown group. There was no increase in median FC-MTB interval (respectively 35, 29 and 28 days) between the lockdown and post-lockdown groups compared to the control group (respectively P=0.2298 and P=0.0153). Likewise, there was no increase in MTB-T interval (27, 20 and 26 days respectively) (P=0.4203). CONCLUSION No increase in wait times was observed during the lockdown and post-lockdown periods in our center.
Collapse
Affiliation(s)
- T Vanderhaegen
- ENT and Head and Neck Department, Huriez Hospital, Lille University, CHU Lille, rue Michel-Polonovski, 59037 Lille cedex, France
| | - A Pierache
- METRICS: Evaluation des Technologies de Santé et des Pratiques Médicales - ULR 2694 - University Lille - CHU Lille, 59000 Lille, France
| | - G Mortuaire
- ENT and Head and Neck Department, Huriez Hospital, Lille University, CHU Lille, rue Michel-Polonovski, 59037 Lille cedex, France
| | - B Rysman
- ENT and Head and Neck Department, Huriez Hospital, Lille University, CHU Lille, rue Michel-Polonovski, 59037 Lille cedex, France
| | - R Nicot
- Service de stomatologie et de chirurgie maxillo-faciale, hôpital Roger Salengro, université de Lille, CHU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France
| | - D Chevalier
- ENT and Head and Neck Department, Huriez Hospital, Lille University, CHU Lille, rue Michel-Polonovski, 59037 Lille cedex, France; CANTHER "Cancer Heterogeneity, Plasticity and Resistance to Therapies", UMR9020 CNRS - U1277 Inserm - Université de Lille - CHU de Lille-COL, 59037 Lille cedex, France
| | - F Mouawad
- ENT and Head and Neck Department, Huriez Hospital, Lille University, CHU Lille, rue Michel-Polonovski, 59037 Lille cedex, France; CANTHER "Cancer Heterogeneity, Plasticity and Resistance to Therapies", UMR9020 CNRS - U1277 Inserm - Université de Lille - CHU de Lille-COL, 59037 Lille cedex, France.
| |
Collapse
|
3
|
Paillaud E, Brugel L, Bertolus C, Baron M, Bequignon E, Caillet P, Schouman T, Lacau Saint Guily J, Périé S, Bouvard E, Laurent M, Salvan D, Chaumette L, de Decker L, Piot B, Barry B, Raynaud-Simon A, Sauvaget E, Bach C, Bizard A, Bounar A, Minard A, Aziz B, Chevalier E, Chevalier D, Gaxatte C, Malard O, Liuu E, Lacour S, Gregoire L, Lafont C, Canouï-Poitrine F. Effectiveness of Geriatric Assessment-Driven Interventions on Survival and Functional and Nutritional Status in Older Patients with Head and Neck Cancer: A Randomized Controlled Trial (EGeSOR). Cancers (Basel) 2022; 14:cancers14133290. [PMID: 35805060 PMCID: PMC9265581 DOI: 10.3390/cancers14133290] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Revised: 06/30/2022] [Accepted: 07/03/2022] [Indexed: 12/10/2022] Open
Abstract
Simple Summary Due to population ageing, there is an increasing number of older patients with head and neck cancers (HNC). Management of HNCs is complex. This population may be frailer than other patients with solid cancer. The Geriatric Assessment (GA) is a multidimensional diagnostic and therapeutic tool focused on frailty to propose a coordinated treatment plan and long-term follow-up. Several trials assessed the efficacy of GA-driven interventions on diverse outcomes but no recent randomized controlled trial demonstrated the impact on mortality, functional, or nutritional status as a primary outcome in this particular population. This trial highlighted several difficulties in implementation of geriatric interventions and suggested that the assessment of other models as co-management with oncologists and/or experienced practice nurses could be useful in clinical routine practice. Abstract This study assesses the efficacy of Geriatric Assessment (GA)-driven interventions and follow-up on six-month mortality, functional, and nutritional status in older patients with head and neck cancer (HNC). HNC patients aged 65 years or over were included between November 2013 and September 2018 by 15 Ear, Nose, and Throat (ENT) and maxillofacial surgery departments at 13 centers in France. The study was of an open-label, multicenter, randomized, controlled, and parallel-group design, with independent outcome assessments. The patients were randomized 1:1 to benefit from GA-driven interventions and follow-up versus standard of care. The interventions consisted in a pre-therapeutic GA, a standardized geriatric intervention, and follow-up, tailored to the cancer-treatment plan for 24 months. The primary outcome was a composite criterion including six-month mortality, functional impairment (fall in the Activities of Daily Living (ADL) score ≥2), and weight loss ≥10%. Among the patients included (n = 499), 475 were randomized to the experimental (n = 238) or control arm (n = 237). The median age was 75.3 years [70.4–81.9]; 69.5% were men, and the principal tumor site was oral cavity (43.9%). There were no statistically significant differences regarding the primary endpoint (n = 98 events; 41.0% in the experimental arm versus 90 (38.0%); p = 0.53), or for each criterion (i.e., death (31 (13%) versus 27 (11.4%); p = 0.48), weight loss of ≥10% (69 (29%) versus 65 (27.4%); p = 0.73) and fall in ADL score ≥2 (9 (3.8%) versus 13 (5.5%); p = 0.35)). In older patients with HNC, GA-driven interventions and follow-up failed to improve six-month overall survival, functional, and nutritional status.
Collapse
Affiliation(s)
- Elena Paillaud
- IMRB, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Est Créteil, F-94010 Créteil, France; (P.C.); (M.L.); (C.L.); (F.C.-P.)
- Département de Gériatrie, Paris Cancer Institute CARPEM, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75015 Paris, France
- Correspondence: ; Tel.: +33-156-09-33-10
| | - Lydia Brugel
- Service d’ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Intercommunal de Créteil, F-94010 Créteil, France; (L.B.); (E.B.)
| | - Chloe Bertolus
- Service de Chirurgie Maxillo-Faciale, Sorbonne Université, Hôpital Pitié Salpétrière, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75013 Paris, France; (C.B.); (T.S.)
| | - Melany Baron
- Service de Soins de Suites et de Réadaptation Gériatrique, Sorbonne Université, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Assistance-Publique Hôpitaux de Paris (AP-HP), F-94205 Ivry sur Seine, France;
| | - Emilie Bequignon
- Service d’ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Intercommunal de Créteil, F-94010 Créteil, France; (L.B.); (E.B.)
| | - Philippe Caillet
- IMRB, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Est Créteil, F-94010 Créteil, France; (P.C.); (M.L.); (C.L.); (F.C.-P.)
- Département de Gériatrie, Paris Cancer Institute CARPEM, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75015 Paris, France
| | - Thomas Schouman
- Service de Chirurgie Maxillo-Faciale, Sorbonne Université, Hôpital Pitié Salpétrière, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75013 Paris, France; (C.B.); (T.S.)
| | - Jean Lacau Saint Guily
- Département d’ORL, Sorbonne Université, Hôpital Tenon, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75020 Paris, France; (J.L.S.G.); (S.P.)
- Département d’ORL, J Lacau St Guily Exerce à l’Hôpital-Fondation Rothschild, S Périé Exerce à la Clinique Hartmann, F-92200 Neuilly Sur Seine, France
| | - Sophie Périé
- Département d’ORL, Sorbonne Université, Hôpital Tenon, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75020 Paris, France; (J.L.S.G.); (S.P.)
- Département d’ORL, J Lacau St Guily Exerce à l’Hôpital-Fondation Rothschild, S Périé Exerce à la Clinique Hartmann, F-92200 Neuilly Sur Seine, France
| | - Eric Bouvard
- Service de Gériatrie, Hôpital Tenon, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75020 Paris, France;
| | - Marie Laurent
- IMRB, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Est Créteil, F-94010 Créteil, France; (P.C.); (M.L.); (C.L.); (F.C.-P.)
- Département de Gériatrie, Hôpital Henri-Mondor, Assistance-Publique Hôpitaux de Paris (AP-HP), F-94010 Créteil, France
| | - Didier Salvan
- Service ORL et Cervico-Facial, Centre Hospitalier Sud Francilien, F-91100 Corbeil-Essonnes, France;
| | - Laurence Chaumette
- Service de Court Sejour Gériatrique, Centre Hospitalier Sud Francilien, F-91100 Corbeil-Essonnes, France;
| | - Laure de Decker
- Service de Gériatrie, Centre Hospitalier Universitaire de Nantes, F-44093 Nantes, France;
| | - Benoit Piot
- Service de Chirurgie Maxillo-Faciale et Stomatologie, Centre Hospitalier Universitaire de Nantes, F-44093 Nantes, France;
| | - Beatrix Barry
- Service ORL et Chirurgie Cervico-Faciale, Université de Paris, Hôpital Bichat, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75018 Paris, France;
| | - Agathe Raynaud-Simon
- Service de Gériatrie, Université Paris Cité, Hôpital Bichat, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75018 Paris, France;
| | - Elisabeth Sauvaget
- Service ORL et Chirurgie Cervico-Faciale, Groupe Hospitalier Paris-Saint Joseph, F-75014 Paris, France;
| | | | - Antoine Bizard
- Unité de Gériatrie Aigue, Hôpital Foch, F-92150 Suresnes, France;
| | - Abderrahmane Bounar
- Unité de Gériatrie Aigue, Centre Hospitalier Intercommunal Villeneuve-Saint-Georges, F-94190 Villeneuve-Saint-Georges, France;
| | - Aurelien Minard
- Service de Gériatrie, Hôpital Léopold Bellan, F-75014 Paris, France;
| | - Bechara Aziz
- Service ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Intercommunal Villeneuve-Saint-Georges, F-94190 Villeneuve-Saint-Georges, France;
| | - Eric Chevalier
- Service ORL et Chirurgie Cervico-Faciale, Groupement Hospitalier Intercommunal Le Raincy-Montfermeil, F-93370 Montfermeil, France;
| | - Dominique Chevalier
- Service ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire de Lille, Hôpital Huriez, F-59000 Lille, France;
| | - Cedric Gaxatte
- Service de Médecine Gériatrique, Centre Hospitalier Universitaire de Lille, F-59000 Lille, France;
| | - Olivier Malard
- Service d’ORL et de Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire de Nantes, F-44093 Nantes, France;
| | - Evelyne Liuu
- Service de Gériatrie, Centre Hospitalier Universitaire de Poitiers, F-86021 Poitiers, France;
| | - Sandrine Lacour
- Centre de Recherche Clinique, Centre Hospitalier Intercommunal de Créteil, F-94010 Créteil, France;
| | - Laetitia Gregoire
- Unité de Recherche Clinique (URC-Mondor), Hôpital Henri-Mondor, AP-HP, F-94010 Créteil, France;
| | - Charlotte Lafont
- IMRB, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Est Créteil, F-94010 Créteil, France; (P.C.); (M.L.); (C.L.); (F.C.-P.)
- Service de Santé Publique, Hôpital Henri-Mondor, Assistance-Publique Hôpitaux de Paris (AP-HP), F-94010 Créteil, France
| | - Florence Canouï-Poitrine
- IMRB, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Est Créteil, F-94010 Créteil, France; (P.C.); (M.L.); (C.L.); (F.C.-P.)
- Service de Santé Publique, Hôpital Henri-Mondor, Assistance-Publique Hôpitaux de Paris (AP-HP), F-94010 Créteil, France
| |
Collapse
|
4
|
Dahan LS, Giorgi R, Vergez S, Le Taillandier de Gabory L, Costes-Martineau V, Herman P, Poissonnet G, Mauvais O, Malard O, Garrel R, Uro-Coste E, Barry B, Bach C, Chevalier D, Mouawad F, Merol JC, Bastit V, Thariat J, Gilain L, Dufour X, Righini CA, Moya-Plana A, Even C, Radulesco T, Michel J, Baujat B, Fakhry N, Albert S, Andry G, Babin E, Bach C, Badet JM, Badoual C, Baglin A, Banal A, Barry B, Baudin E, Baujat B, Bensadoun R, Bertolus C, Bessède JP, Blanchard D, Borel C, Bozorg-Grayeli A, Breheret R, Breton P, Brugel L, Calais G, Casiraghi O, Cassagnau E, Castillo L, Ceruse P, Chabolle F, Chevalier D, Chobaut J, Choussy O, Cosmidis A, Coste A, Costes V, Crampette L, Darrouzet V, Demez P, Dessi P, Devauchelle B, Dolivet G, Dubrulle F, Duflo S, Dufour X, Faivre S, Fakhry N, Ferron C, Floret F, de Gabory L, Garrel R, Geoffrois L, Gilain L, Giovanni A, Girod A, Guerrier B, Hans S, Herman P, Hofman P, Housset M, Jankowski R, Jegoux F, Juliéron M, Kaminsky MC, Kolb F, St Guily JL, Laccoureye L, Lallemant B, Lang P, Lartigau E, Lavieille JP, Lefevre M, Leroy X, Malard O, Massip F, Mauvais O, Merol JC, Michel J, Mom T, Morinière S, de Monès E, Moulin G, Noel G, Poissonnet G, Prades JM, Radulesco T, de Raucourt D, Reyt E, Righini C, Robin YM, Rolland F, Ruhin B, Sarroul N, Schultz P, Serrano E, Sterkers O, Strunski V, Sudaka A, Tassart M, Testelin S, Thariat J, Timochenko A, Toussaint B, Coste EU, Valette G, Van den Abbeele T, Varoquaux A, Veillon F, Vergez S, Wassef M. Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases. Eur J Surg Oncol 2021; 47:1376-1383. [DOI: 10.1016/j.ejso.2020.11.123] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 10/31/2020] [Accepted: 11/13/2020] [Indexed: 12/18/2022] Open
|
5
|
Alkasbi J, Mortuaire G, Rysman B, Nicot R, Chevalier D, Mouawad F. Match between therapeutic proposal in multidisciplinary tumor board and actual treatment in head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2020; 138:247-252. [PMID: 33257266 DOI: 10.1016/j.anorl.2020.11.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVES There are few published studies evaluating the quality and outcome of multidisciplinary tumor board (MDTB) decisions. The aim of the present study was to evaluate adherence to MDTB recommendations in head and neck cancer and to document reasons in case of discordance. MATERIAL AND METHODS We included all patients with newly diagnosed head and neck cancer presented in our MDTB meetings between January 1st and December 31st, 2018, whatever the tumor site, histology type and TNM classification. MDTB recommendations were compared to actual treatment. Discordance was defined as treatment partially or entirely different from the treatment decision recorded in the MDTB minutes. RESULTS Board decisions were made for 344 new patients. Complete treatment concordance rate was 91.6% (315/344 patients), with deviation in 29 patients. Reasons for deviation were complications of treatment in 10 cases, patient refusal in 8, and physician's decision in 4 cases. Five patients died before therapy initiation. Mean interval from board discussion to treatment was 21 days, and depended on type of treatment (range, 1 to 74 days). CONCLUSION This study shows the importance of evaluating concordance between the protocol proposed in the MDTB and the treatment actually received, to identify factors for deviation and remedy them when possible.
Collapse
Affiliation(s)
- J Alkasbi
- Service d'ORL et de Chirurgie Cervico-Faciale, Hôpital Huriez, CHU de Lille, Université de Lille, rue Michel Polonovski, 59037 Lille cedex, France
| | - G Mortuaire
- Service d'ORL et de Chirurgie Cervico-Faciale, Hôpital Huriez, CHU de Lille, Université de Lille, rue Michel Polonovski, 59037 Lille cedex, France
| | - B Rysman
- Service d'ORL et de Chirurgie Cervico-Faciale, Hôpital Huriez, CHU de Lille, Université de Lille, rue Michel Polonovski, 59037 Lille cedex, France
| | - R Nicot
- Service de Stomatologie et de Chirurgie Maxillo-Faciale, Hôpital Roger Salengro, CHU de Lille, Université de Lille, Rue Michel Polonovski, 59037 Lille cedex, France
| | - D Chevalier
- Service d'ORL et de Chirurgie Cervico-Faciale, Hôpital Huriez, CHU de Lille, Université de Lille, rue Michel Polonovski, 59037 Lille cedex, France
| | - F Mouawad
- Service d'ORL et de Chirurgie Cervico-Faciale, Hôpital Huriez, CHU de Lille, Université de Lille, rue Michel Polonovski, 59037 Lille cedex, France; Inserm U 908, Lille Science and Technology University, UFR de Biologie - SN3, 59655 Villeneuve d'Ascq, France.
| |
Collapse
|
6
|
Manalayil J, Muston A, Ball A, Chevalier D. 1HR ON-CALL - Using Simulated ON-CALL to Underpin Experiential Learning in Final Year Medical Students. J Eur CME 2020; 9:1832749. [PMID: 33224625 PMCID: PMC7655053 DOI: 10.1080/21614083.2020.1832749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
A survey of Blackpool Foundation Year One (FY1) doctors found limited training about being on-call. We could not find any direct mention in Tomorrow’s Doctors for preparing undergraduates for this.1Tomorrow’s Doctors: Outcomes and standards for undergraduate medical education [Internet]. 1st ed. 2009 [cited 30 February 2015]. Available from: http://www.gmc-uk.org/Tomorrow_s_Doctors_1214.pdf_48905759.pdf Working out of hours, on-call and with a reduced workforce is a known area of anxiety among junior doctors. With few examples in literature,2Dickinson M, Pimblett M, Hanson J, Davis M. Reflecting reality: pager simulations in undergraduate education. The Clinical Teacher. 2014;11(6):421–424. ,3Fisher J, Martin R, Tate D. Hands on + hands free: simulated on-call interaction. The Clinical Teacher. 2014;11(6):425–428. we developed a novel approach to aiding final-year medical students prepare for this. A simulated teaching programme allowed students to experience the pressures of working on-call. We hoped to imitate stressors within a safe environment. Students were each given a bleep for an hour. Supervisors role-playing a concerned nurse “bleeped” the students. Each task was held in a folder on different wards (no patient interaction or information was involved). They were relatively simple and designed to stimulate resourcefulness, communication and triage skills. Various resources were available including the number for the medical registrar, played by supervisors. The final station was always the unwell patient aimed at drawing the student immediately to this scenario. A facilitated feedback session explored students’ positive and negative experiences, concerns and coping mechanisms. Over the three years of this running, results were resoundingly positive with students taking great confidence from the programme. During the open feedback session, students valued using open wards and having to navigate in an unfamiliar hospital as a realistic preparation for next year. Being on-call is an inevitable part of a junior doctor’s work and we believe there is scope for better preparation within undergraduate training. We have developed an effective and sustainable simulation that has shown excellent results. Due to the positive reaction and low maintenance of the project, we aim to cement our teaching programme as a permanent feature for undergraduate students at Blackpool Victoria Hospital.
Collapse
Affiliation(s)
- J Manalayil
- Blackpool Victoria Hospital, Blackpool and Fylde NHS Foundation Trust, Blackpool, England, UK
| | - A Muston
- Blackpool Victoria Hospital, Blackpool and Fylde NHS Foundation Trust, Blackpool, England, UK
| | - A Ball
- Blackpool Victoria Hospital, Blackpool and Fylde NHS Foundation Trust, Blackpool, England, UK
| | - D Chevalier
- Blackpool Victoria Hospital, Blackpool and Fylde NHS Foundation Trust, Blackpool, England, UK
| |
Collapse
|
7
|
Vergez S, Fakhry N, Cartier C, Kennel T, Courtade-Saidi M, Uro-Coste E, Varoquaux A, Righini CA, Malard O, Mogultay P, Thariat J, Tronche S, Garrel R, Chevalier D. Guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL), part I: Primary treatment of pleomorphic adenoma. Eur Ann Otorhinolaryngol Head Neck Dis 2020; 138:269-274. [PMID: 33060032 DOI: 10.1016/j.anorl.2020.09.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
INTRODUCTION The authors present the guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL) for the diagnosis and treatment of pleomorphic adenoma (PA) of the salivary glands. METHOD A review of the literature was performed by a multidisciplinary task force. Guidelines were drafted based on the articles retrieved and the workgroup members' individual experience. Guidelines were graded A, B, C or expert opinion by decreasing level of evidence. RESULTS In clinically suspected salivary gland PA, MRI should be performed, including head and neck lymph node levels. Fine needle aspiration cytology is particularly recommended for tumours difficult to characterise by MRI. Frozen section biopsy should be performed to confirm diagnosis and adapt the surgical procedure in case of intraoperative findings of malignancy. Complete resection of the parotid PA should be performed en bloc, including margins, when feasible according to tumour location, while respecting the facial nerve. Enucleation (resection only in contact with the tumour) is not recommended. For the accessory salivary and submandibular glands, complete en bloc resection should be performed.
Collapse
Affiliation(s)
- S Vergez
- Service d'ORL et de chirurgie de la face et du cou, hôpital Larrey, institut universitaire du cancer de Toulouse Oncopole, CHU de Toulouse, Toulouse, France.
| | - N Fakhry
- Service d'ORL et chirurgie de la face et du cou, hôpital de la conception, AP-HM, Aix-Marseille Université, Marseille, France
| | - C Cartier
- Service d'ORL et de chirurgie de la face et du cou, CHU de Montpellier, Montpellier, France
| | - T Kennel
- Service d'ORL et de chirurgie de la face et du cou, CHU de Montpellier, Montpellier, France
| | - M Courtade-Saidi
- Service d'anatomie et cytologie pathologiques, institut universitaire du cancer de Toulouse Oncopole, INSERM CRCT-Équipe 11, Toulouse, France
| | - E Uro-Coste
- Service d'anatomie et cytologie pathologiques, institut universitaire du cancer de Toulouse Oncopole, INSERM CRCT-Équipe 11, Toulouse, France
| | - A Varoquaux
- Service de radiologie, hôpital de la conception, AP-HM, Marseille; AMU, Faculté de Médecine Timone CNRS-Centre for Magnetic Resonance in Biology and Medicine, Marseille, France
| | - C-A Righini
- Service d'ORL et de chirurgie de la face et du cou, CHU de Grenoble Alpes (CHUGA), Grenoble, France
| | - O Malard
- Service d'ORL et de chirurgie de la face et du cou, CHU Hôtel Dieu, Nantes, France
| | - P Mogultay
- Service d'ORL et de chirurgie de la face et du cou, CHU de Montpellier, Montpellier, France
| | - J Thariat
- Département de radiothérapie, centre François-Baclesse, Caen; Laboratoire de Physique Corpusculaire IN2P3/ENSICAEN-UMR6534-Unicaen-Normandie Université, Caen, France
| | - S Tronche
- Société française d'ORL et chirurgie cervico-faciale, Strasbourg, France
| | - R Garrel
- Service d'ORL et de chirurgie de la face et du cou, CHU de Montpellier, Montpellier, France
| | - D Chevalier
- Service d'ORL et de chirurgie de la face et du cou, CHU de Lille, Lille, France
| |
Collapse
|
8
|
Franco A, Tresch E, Sakji I, Makhloufi S, Abdeddaim C, Julieron M, Dansin E, Chevalier D, Mouawad F, Lefebvre G. 952P Neutrophil-to-lymphocyte ratio (NLR) and survival in recurrent or metastatic head and neck cancer patients treated with immunotherapy. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Malard O, Thariat J, Cartier C, Chevalier D, Courtade-Saidi M, Uro-Coste E, Garrel R, Kennel T, Mogultay P, Tronche S, Varoquaux A, Righini CA, Vergez S, Fakhry N. Guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL), part II: Management of recurrent pleomorphic adenoma of the parotid gland. Eur Ann Otorhinolaryngol Head Neck Dis 2020; 138:45-49. [PMID: 32800715 DOI: 10.1016/j.anorl.2020.08.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
INTRODUCTION The authors present the guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL) for the management of recurrent pleomorphic adenoma (RPA) of the parotid gland. METHOD A review of the literature was performed by a multidisciplinary task force. Guidelines were drafted, based on the articles retrieved and the work group members' individual experience. There were then read and re-edited by an independent reading group. The proposed recommendations were graded A, B or C on decreasing levels of evidence. RESULTS Complete resection under neuromonitoring is recommended in case of RPA. The risks of progression and malignant transformation, which are higher the younger the patient, have to be taken into consideration. The risk of functional sequelae must be explained to the patient. MRI is recommended ahead of any surgery for parotid RPA, to determine extension and detect subclinical lesions. Radiotherapy should be considered in case of multi-recurrent pleomorphic adenoma after macroscopically complete revision surgery at high risk of new recurrence (microscopic residual disease), in case of RPA after incomplete resection, and in non-operable RPA.
Collapse
Affiliation(s)
- O Malard
- Service d'ORL et de Chirurgie de la Face et du Cou, CHU Hôtel Dieu, Nantes, France
| | - J Thariat
- Département de Radiothérapie, Centre François Baclesse, Laboratoire de Physique Corpusculaire IN2P3/ENSICAEN-UMR6534-Unicaen-Normandie Université, Caen, France
| | - C Cartier
- Service d'ORL et de Chirurgie de la Face et du Cou, CHU de Montpellier, France
| | - D Chevalier
- Service d'ORL et de Chirurgie de la Face et du Cou, CHU de Lille, France
| | - M Courtade-Saidi
- Service d'Anatomie et Cytologie Pathologiques, Institut Universitaire du Cancer de Toulouse Oncopole, Inserm CRCT-Équipe 11, Toulouse, France
| | - E Uro-Coste
- Service d'Anatomie et Cytologie Pathologiques, Institut Universitaire du Cancer de Toulouse Oncopole, Inserm CRCT-Équipe 11, Toulouse, France
| | - R Garrel
- Service d'ORL et de Chirurgie de la Face et du Cou, CHU de Montpellier, France
| | - T Kennel
- Service d'ORL et de Chirurgie de la Face et du Cou, CHU de Montpellier, France
| | - P Mogultay
- Service d'ORL et de Chirurgie de la Face et du Cou, CHU de Montpellier, France
| | - S Tronche
- Société Française d'ORL et Chirurgie Cervico-Faciale, France
| | - A Varoquaux
- Service de radiologie du Pr Chagnaud, Hôpital de la Conception, AP-HM, AMU, Faculté de Médecine Timone CNRS-Center for Magnetic Resonance in Biology and Medicine, France
| | - C A Righini
- Service d'ORL et de Chirurgie de la Face et du Cou, CHU de Grenoble Alpes (CHUGA), France
| | - S Vergez
- Service d'ORL et de Chirurgie de la Face et du Cou, Hôpital Larrey, CHU de Toulouse, Département de Chirurgie, Institut Universitaire du Cancer de Toulouse Oncopole, France
| | - N Fakhry
- Service d'ORL et Chirurgie de la Face et du Cou, Hôpital de la Conception, APHM, Aix-Marseille Université, Marseille, France.
| |
Collapse
|
10
|
Saloner Dahan L, Giorgi R, Garrel R, Le Taillandier de Gabory L, Costes-Martineau V, Herman P, Poissonnet G, Mauvais O, Malard O, Vergez S, Uro-Coste E, Barry B, Bach C, Chevalier D, Mouawad F, Merol JC, Bastit V, Thariat J, Gilain L, Dufour X, Righini CA, Dessi P, Michel J, Radulesco T, Even C, Baujat B, Fakhry N. Management of cN0 low-grade mucoepidermoid carcinomas of salivary glands: Prospective multicentre study of 152 cases of the French Network of Rare Head and Neck Tumors (REFCOR). Clin Otolaryngol 2020; 45:926-931. [PMID: 32569444 DOI: 10.1111/coa.13600] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Revised: 05/28/2020] [Accepted: 06/14/2020] [Indexed: 02/01/2023]
Affiliation(s)
- Laurie Saloner Dahan
- Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, Marseille, France.,Aix Marseille Univ, Marseille, France.,REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France
| | - Roch Giorgi
- Aix Marseille Univ, Marseille, France.,Faculté des Sciences Médicales et Paramédicales, SESSTIM, Marseille, France.,BIOSTIC, Hôpital de la Timone, Marseille, France
| | - Renaud Garrel
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et Chirurgie cervico-faciale, CHU de Montpellier, Montpellier, France
| | - Ludovic Le Taillandier de Gabory
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et Chirurgie cervico-faciale, CHU de Bordeaux, Bordeaux, France
| | - Valérie Costes-Martineau
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'Anatomie Pathologique, CHU de Montpellier, Montpellier, France
| | - Philippe Herman
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL Chirurgie maxillo-faciale et plastique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Gilles Poissonnet
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, Centre Antoine Lacassagne, Institut Universitaire de la face et du cou, Nice, France
| | - Olivier Mauvais
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL Chirurgie cervico-faciale, Audiophoniatrie, CHU de Besançon, Besancon, France
| | - Olivier Malard
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, CHU de Nantes, Nantes, France
| | - Sébastien Vergez
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, CHU de Toulouse/Oncopôle, Toulouse, France
| | - Emmanuelle Uro-Coste
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'Anatomie et Cytologie Pathologiques, Institut Universitaire du Cancer-Oncopole, Toulouse, France
| | - Béatrix Barry
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, CHU Paris Nord-Val de Seine, Hôpital Xavier Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Christine Bach
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie de la face et du cou, Hôpital Foch, Suresnes, France
| | - Dominique Chevalier
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, CHU de Lille, Lille, France
| | - Francois Mouawad
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, CHU de Lille, Lille, France
| | - Jean-Claude Merol
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, CHU de reims, Reims, France
| | - Vianney Bastit
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, Centre François Baclesse, Caen, France
| | - Juliette Thariat
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, Centre François Baclesse, Caen, France
| | - Laurent Gilain
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Xavier Dufour
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, CHU de Poitiers, Poitiers, France
| | - Christian-Adrien Righini
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et chirurgie cervico-faciale, CHU de Grenoble, Grenoble, France
| | - Patrick Dessi
- Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, Marseille, France.,Aix Marseille Univ, Marseille, France.,REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France
| | - Justin Michel
- Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, Marseille, France.,Aix Marseille Univ, Marseille, France.,REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France
| | - Thomas Radulesco
- Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, Marseille, France.,Aix Marseille Univ, Marseille, France.,REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France
| | - Caroline Even
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'Oncologie médicale tête et cou, Institut Gustave Roussy, Villejuif, France
| | - Bertrand Baujat
- REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France.,Service d'ORL et Chirurgie Cervico-faciale, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Nicolas Fakhry
- Service d'ORL et Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire La Conception, Marseille, France.,Aix Marseille Univ, Marseille, France.,REFCOR (Réseau d'Expertise Français sur les Cancers ORL Rares), Paris, France
| |
Collapse
|
11
|
Nakayama M, Holsinger FC, Chevalier D, Orosco RK. The dawn of robotic surgery in otolaryngology-head and neck surgery. Jpn J Clin Oncol 2019; 49:404-411. [PMID: 30796834 DOI: 10.1093/jjco/hyz020] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2018] [Revised: 01/14/2019] [Accepted: 01/30/2019] [Indexed: 11/13/2022] Open
Abstract
Transoral robotic surgery (TORS) utilizing the da Vinci robotic system has opened a new era for minimally-invasive surgery (MIS) in Otolaryngology-Head and Neck Surgery. Awareness of the historical steps in developing robotic surgery (RS) and understanding its current application within our field can help open our imaginations to future of the surgical robotics. We compiled a historical perspective on the evolution of surgical robotics, the road to the da Vinci surgical system, and conducted a review of TORS regarding clinical applications and limitations, prospective clinical trials and current status in Japan. We also provided commentary on the future of surgical robotics within our field. Surgical robotics grew out of the pursuit of telerobotics and the advances in robotics for non-medical applications. Today in our field, cancers and diseases of oropharynx and supraglottis are the most common indications for RS. It has proved capable of preserving the laryngopharyngeal function without compromising oncologic outcomes, and reducing the intensity of adjuvant therapy. TORS has become a standard modality for MIS, and will continue to evolve in the future. As robotic surgical systems evolve with improved capabilities in visual augmentation, spatial navigation, miniaturization, force-feedback and cost-effectiveness, we will see further advances in the current indications, and an expansion of indications. By promoting borderless international collaborations that put 'patients first', the bright future of surgical robotics will synergistically expand to the limits of our imaginations.
Collapse
Affiliation(s)
- Meijin Nakayama
- Department of Otorhinolaryngology-Head and Neck Surgery, Yokohama City University, Yokohama, Japan
| | - F Christopher Holsinger
- Department of Otolaryngology, Division of Head and Neck Surgery, Stanford University, Palo Alto, California, USA
| | - Dominique Chevalier
- Department of Ear, Nose, Throat-Head and Neck Surgery, Huriez Hospital, University of Lille, Lille, France
| | - Ryan K Orosco
- Department of Surgery, Division of Head and Neck Surgery, University of California San Diego, La Jolla, California, USA
| |
Collapse
|
12
|
Nakayama M, Holsinger FC, Chevalier D, Orosco RK. Erratum: The dawn of robotic surgery in otolaryngology-head and neck surgery. Jpn J Clin Oncol 2019; 49:493. [PMID: 30957174 DOI: 10.1093/jjco/hyz058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Indexed: 11/13/2022] Open
|
13
|
Chaillou D, Mortuaire G, Deken-Delannoy V, Rysman B, Chevalier D, Mouawad F. Presence in head and neck cancer multidisciplinary team meeting: The patient's experience and satisfaction. Eur Ann Otorhinolaryngol Head Neck Dis 2018; 136:75-82. [PMID: 30503380 DOI: 10.1016/j.anorl.2018.10.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND In oncology, multi-disciplinary team meetings improve overall survival and reduce time to treatment in head and neck cancer. Interestingly, no study has examined the experience of patients attending an MTM. The present study addressed two questions: Does the MTM cause anxiety/depression for patients who are present? Are patients satisfied at the end of the meeting? PATIENTS AND METHODS The study included all patients attending an MTM, who agreed to participate in the study and who fully completed two questionnaires. The Hospital Anxiety and Depression Scale (HADS) and a satisfaction questionnaire were filled out at three time-points: T0 before MTM, T1 at end of MTM, and T2 1 month after MTM for the HADS; and T1 and T2 for the satisfaction questionnaire. RESULTS There were no significant differences in the number of patients experiencing anxiety between T0 and T1 (P=0.6085), T0 and T2 (P=1) or T1 and T2 (P=1). Likewise, there were no significant differences in the number of patients in depression between T0 and T1 (P=0.9397), T0 and T2 (P=1) or T1 and T2 (P=1). Mean satisfaction was good (question 14 on the satisfaction questionnaire: 8.7/10 at T1 and 7.7/10 at T2), but with a significant decrease between T1 and T2 (P=0.0009: i.e.,<0.05). Percentage information remembered (question 12) significantly decreased between T1 (mean 86%, standard deviation 0.2, median 94%) and T2 (78%±0.2, median 81%) (P=0.03). Presence in the MTM did not appear to induce or increase anxiety or pre-existing depressive syndrome.
Collapse
Affiliation(s)
- D Chaillou
- Service d'ORL et de chirurgie cervicofaciale, hôpital Huriez, université de Lille, CHRU de Lille, rue Michel-Polonovski, 59000 Lille, France
| | - G Mortuaire
- Service d'ORL et de chirurgie cervicofaciale, hôpital Huriez, université de Lille, CHRU de Lille, rue Michel-Polonovski, 59000 Lille, France
| | - V Deken-Delannoy
- Unité de méthodologie, biostatistique et data management, Maison régionale de la recherche clinique, CHRU de Lille, rue du Professeur Laguesse, 59037 Lille, France
| | - B Rysman
- Service d'ORL et de chirurgie cervicofaciale, hôpital Huriez, université de Lille, CHRU de Lille, rue Michel-Polonovski, 59000 Lille, France
| | - D Chevalier
- Service d'ORL et de chirurgie cervicofaciale, hôpital Huriez, université de Lille, CHRU de Lille, rue Michel-Polonovski, 59000 Lille, France
| | - F Mouawad
- Service d'ORL et de chirurgie cervicofaciale, hôpital Huriez, université de Lille, CHRU de Lille, rue Michel-Polonovski, 59000 Lille, France; Service d'ORL et de chirurgie cervicofaciale, Inserm U 908, hôpital Huriez, université de Lille, CHRU de Lille, rue Michel-Polonovski, 59000 Lille, France.
| |
Collapse
|
14
|
Gupta R, Chevalier D, Saluja J, Lau C, Wang C, Fakih M. ctDNA assays identify alterations in RAS, EGFR, and cMET that are unique to RAS-WT patients progressing on anti-EGFR therapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Amanam I, Chao J, Lim D, Rahmanuddin S, Schrock A, Ali S, Lau C, Chevalier D, Harris E, Saluja J, Wang C, Fakih M. Lower tumor mutational burden (TMB) and hepatic metastases may predict for lack of response to PD-1 blockade in MSI-H metastatic colorectal cancer (MCRC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Chevalier D, Ahmed I. Giant atrial myxoma: First presentation of acute pulmonary oedema. Int J Surg 2018. [DOI: 10.1016/j.ijsu.2018.05.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Vannimenus C, Bricout H, Le Rouzic O, Mouawad F, Chevalier D, Dansin E, Rotsaert L, Lefebvre G, Cottencin O, Porte H, Scherpereel A, El Fahsi A, Richard F, Rolland B. Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study. BMC Cancer 2018; 18:372. [PMID: 29614983 PMCID: PMC5883294 DOI: 10.1186/s12885-018-4253-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Accepted: 03/20/2018] [Indexed: 11/26/2022] Open
Abstract
Background Active smoking at the time of diagnosis of a first head & neck (H&N) or lung cancer is associated with a worse cancer outcome and increased mortality. However, the compared characteristics of active vs. former smokers at cancer diagnosis are poorly known. Methods In 371 subjects with a first H&N or lung cancer, we assessed: 1) socio-demographic features; 2) lifelong types of smoking; 3) alcohol use disorder identification test (AUDIT); 4) cannabis abuse screening test (CAST); and 5) Mini International Neuropsychiatric Interview (MINI). Using a multivariable regression model, we compared the profile of current smokers and past smokers. Results Current smokers more frequently exhibited H&N cancer (OR 3.91; 95% CI [2.00–6.51]; p < 0.0001) and ever smoking of hand-rolled cigarettes (OR 2.2; 95% CI [1.25–3.88]; p = 0.007). Among subjects with lung cancer (n = 177), current smoking was primarily associated with ever smoking of hand-rolled cigarettes (OR 2.88; 95% CI [1.32–6.30]; p = 0.008) and negatively associated with age (OR 0.92; 95% CI [0.89–0.96]; p < 0.001). Among subjects with H&N cancer (n = 163), current smokers exhibited a significantly greater AUDIT score (OR = 1.08; 95% CI [1.01–1.16]; p = 0.03). Conclusion At the time of diagnosis of the first lung or H&N cancer, current smoking is highly associated with previous type of smoking and alcohol drinking patterns. Trial registration NCT01647425; Registration date: July 23, 2012.
Collapse
Affiliation(s)
- Corinne Vannimenus
- Service de Tabacologie, Clinique de Pneumologie, Hôpital Calmette, CHRU de Lille CS70001, 59037, Lille cedex, France.
| | - Hélène Bricout
- Centre de Référence Régionale en Cancérologie, Lille, France
| | - Olivier Le Rouzic
- Service de Tabacologie, Clinique de Pneumologie, Hôpital Calmette, CHRU de Lille CS70001, 59037, Lille cedex, France
| | | | | | - Eric Dansin
- Département de Cancérologie Cervico-Faciale, Centre de Lutte Contre le Cancer Oscar Lambret, Lille, France
| | - Laurence Rotsaert
- Département de Cancérologie Cervico-Faciale, Centre de Lutte Contre le Cancer Oscar Lambret, Lille, France
| | - Gautier Lefebvre
- Département de Cancérologie Cervico-Faciale, Centre de Lutte Contre le Cancer Oscar Lambret, Lille, France
| | | | - Henri Porte
- Clinique de Chirurgie Thoracique, CHRU de Lille, Lille, France
| | - Arnaud Scherpereel
- Service de Tabacologie, Clinique de Pneumologie, Hôpital Calmette, CHRU de Lille CS70001, 59037, Lille cedex, France
| | - Asmaa El Fahsi
- Centre de Référence Régionale en Cancérologie, Lille, France
| | - Florence Richard
- Santé Publique et Epidémiologie, Institut Pasteur, Université de Lille, INSERM UMR744, Lille, France
| | - Benjamin Rolland
- Univ Lyon; UCBL; INSERM U1028 ; CNRS UMR5292 ; Service Universitaire d'Addictologie de Lyon, CH le Vinatier, Lyon, France
| | | |
Collapse
|
18
|
Fraysse B, Couloigner V, Chevalier D. Foreword. Eur Ann Otorhinolaryngol Head Neck Dis 2018; 135:S1. [PMID: 29463400 DOI: 10.1016/j.anorl.2018.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- B Fraysse
- ENT and head and neck surgery department, university hospital center, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France
| | - V Couloigner
- Pediatric ENT and head and neck surgery department, Necker-Enfants-Malades university hospital, 149, rue de Sèvres, 75015 Paris, France.
| | - D Chevalier
- ENT and head and neck surgery department, Huriez hospital, Lille regional university hospital, 59000 Lille, France
| |
Collapse
|
19
|
Gengler I, Carpentier L, Pasquesoone X, Chevalier D, Mortuaire G. Predictors of unanticipated admission within 30 days of outpatient sinonasal surgery. Rhinology 2017; 55:274-280. [PMID: 28026838 DOI: 10.4193/rhino16.251] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVES To identify predictive factors of readmission after day-case rhinologic surgery. METHODS A 2-year retrospective chart review of patients scheduled for ambulatory sinonasal surgery in a tertiary medical center was conducted. The operating room and the anesthetic files were screened to identify demographic data, types of procedure, comorbidities and post-operative complications. RESULTS From January 2014 to January 2016, 924 outpatient sinonasal procedures were identified. The overall readmission rate within the 30-postoperative days was 5.1% (2.9% for overnight hospital stay, 2.2% for unplanned post procedure visit to the hospital via the emergency room, or directly to the surgical unit within 30 days of discharge). Age at least 50 years, surgical duration at least 80 min, endoscopic sinus surgery procedures and postoperative nasal packing were identified as negative predictive factors of readmission. CONCLUSION Careful scheduling of those higher-risk patients undergoing sinonasal surgery and appropriate postoperative observation should be implemented to improve healthcare quality in an outpatient setting.
Collapse
Affiliation(s)
- I Gengler
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Lille, France
| | - L Carpentier
- Lille Inflammation Research International Center - Inserm U995, Universite de Lille, Lille, France
| | - X Pasquesoone
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Lille, France
| | - D Chevalier
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Lille, France
| | - G Mortuaire
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Lille, France
| |
Collapse
|
20
|
Mortuaire G, Theis D, Fackeure R, Chevalier D, Gengler I. Cost-effectiveness assessment in outpatient sinonasal surgery. Eur Ann Otorhinolaryngol Head Neck Dis 2017; 135:11-15. [PMID: 28927846 DOI: 10.1016/j.anorl.2017.08.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
AIMS To assess the cost-effectiveness of outpatient sinonasal surgery in terms of clinical efficacy and control of expenses. METHODS A retrospective study was conducted from January 2014 to January 2016. Patients scheduled for outpatient sinonasal surgery were systematically included. Clinical data were extracted from surgical and anesthesiology computer files. The cost accounting methods applied in our institution were used to evaluate logistic and technical costs. The standardized hospital fees rating system based on hospital stay and severity in diagnosis-related groups (Groupes homogènes de séjours: GHS) was used to estimate institutional revenue. RESULTS Over 2years, 927 outpatient surgical procedures were performed. The crossover rate to conventional hospital admission was 2.9%. In a day-1 telephone interview, 85% of patients were very satisfied with the procedure. All outpatient cases showed significantly lower costs than estimated for conventional management with overnight admission, while hospital revenue did not differ between the two. CONCLUSION This study confirmed the efficacy of outpatient surgery in this indication. Lower costs could allow savings for the health system by readjusting the rating for the procedure. More precise assessment of cost-effectiveness will require more fine-grained studies based on micro costing at hospital level and assessment of impact on conventional surgical activity and post-discharge community care.
Collapse
Affiliation(s)
- G Mortuaire
- Service d'ORL de chirurgie cervico-faciale, hôpital Huriez, CHRU de Lille, 59000 Lille, France; Inserm U995, Lille Inflammation Research International Center, université de Lille, Lille, France.
| | - D Theis
- Département d'information médicale, université de Lille, Lille, France
| | - R Fackeure
- Département d'anesthésie, université de Lille, Lille, France
| | - D Chevalier
- Service d'ORL de chirurgie cervico-faciale, hôpital Huriez, CHRU de Lille, 59000 Lille, France
| | - I Gengler
- Service d'ORL de chirurgie cervico-faciale, hôpital Huriez, CHRU de Lille, 59000 Lille, France; Inserm U995, Lille Inflammation Research International Center, université de Lille, Lille, France
| |
Collapse
|
21
|
Makhloufi S, Lefebvre G, Sakji I, Feutry F, Leroy T, Penel N, Coche B, Fourquet J, Ghestem F, Julieron M, Chevalier D, Tresch E. Prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) on overall survival in patients treated with chemoradiotherapy for head and neck cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx374.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Jamet N, Thivilliers AP, Paubel P, Chevalier D, Bourguignon S, Bézie Y. [Use of a Delphi survey to assess the hospital economic impact of innovative products: The example of idarucizumab a dabigatran-specific reversal agent]. Ann Pharm Fr 2017; 75:480-488. [PMID: 28818320 DOI: 10.1016/j.pharma.2017.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Revised: 06/20/2017] [Accepted: 06/29/2017] [Indexed: 11/30/2022]
Abstract
OBJECTIVES The economic impact of therapeutic innovations on the hospital patient management cannot be easily estimated. The objective of this study is to illustrate the use of a Delphi survey as a support tool to identify the changes following the use of idarucizumab in dabigatran-treated patients with uncontrolled/life-threatening bleeding or who required emergency surgery/urgent procedures. METHODS The Delphi questionnaires have been administrated to 8 emergency physicians or anesthetists from 6 different hospital centers. Following the answers, an economic valorization has been carried out on every parameter on which a consensus was reached (at least 4 answers showing an identical trend). A mean management cost for each etiology with and without the use of idarucizumab has thus been identified. RESULTS For gastro-intestinal and other life-threatening bleedings (excepted intracranial bleedings), the total management cost of the hospital stay was respectively 6058 € (-35%) and 6219 € (-34%) following the use of the reversal agent. The hospital management cost for intracranial bleeding is slightly increasing to 9790 € (+3%). The cost of a stay for emergency surgery decreases to 6962€ (-2%). CONCLUSIONS This study shows a positive economic impact following the use of the dabigatran-specific reversal agent for patients with uncontrolled/life-threatening bleeding excepted in the case of intracranial bleeding. Moreover, it points out that a Delphi survey is an easy way to predict the hospital economic impact of a therapeutic innovation when no other evaluation is possible.
Collapse
Affiliation(s)
- N Jamet
- Stratégique santé, 52, boulevard de l'Yerres, 91000 Evry, France
| | - A P Thivilliers
- Service pharmacie, groupe hospitalier Paris-Saint-Joseph, 185, rue Raymond-Losserand, 75014 Paris, France
| | - P Paubel
- Assistance publique-Hôpitaux de Paris, agence générale des équipements et des produits de santé, 75005 Paris, France; Faculté de pharmacie de Paris, institut Droit-et-Santé, Inserm UMR S 1145, université Paris-Descartes, Sorbonne Paris Cité, 75006 Paris, France
| | - D Chevalier
- Service pharmacie, groupe hospitalier Paris-Saint-Joseph, 185, rue Raymond-Losserand, 75014 Paris, France
| | - S Bourguignon
- Stratégique santé, 52, boulevard de l'Yerres, 91000 Evry, France
| | - Y Bézie
- Service pharmacie, groupe hospitalier Paris-Saint-Joseph, 185, rue Raymond-Losserand, 75014 Paris, France.
| |
Collapse
|
23
|
Moche H, Paget V, Chevalier D, Lorge E, Claude N, Girard HA, Arnault JC, Chevillard S, Nesslany F. Carboxylated nanodiamonds can be used as negative reference in in vitro nanogenotoxicity studies. J Appl Toxicol 2017; 37:954-961. [PMID: 28165139 DOI: 10.1002/jat.3443] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Revised: 12/19/2016] [Accepted: 12/26/2016] [Indexed: 11/08/2022]
Abstract
Nanodiamonds (NDs) are promising nanomaterials for biomedical applications. However, a few studies highlighted an in vitro genotoxic activity for detonation NDs, which was not evidenced in one of our previous work quantifying γ-H2Ax after 20 and 100 nm high-pressure high-temperature ND exposures of several cell lines. To confirm these results, in the present work, we investigated the genotoxicity of the same 20 and 100 nm NDs and added intermediate-sized NDs of 50 nm. Conventional in vitro genotoxicity tests were used, i.e., the in vitro micronucleus and comet assays that are recommended by the French National Agency for Medicines and Health Products Safety for the toxicological evaluation of nanomedicines. In vitro micronucleus and in vitro comet assays (standard and hOGG1-modified) were therefore performed in two human cell lines, the bronchial epithelial 16HBE14o- cells and the colon carcinoma T84 cells. Our results did not show any genotoxic activity, whatever the test, the cell line or the size of carboxylated NDs. Even though these in vitro results should be confirmed in vivo, they reinforce the potential interest of carboxylated NDs for biomedical applications or even as a negative reference nanoparticle in nanotoxicology. Copyright © 2017 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- H Moche
- Institut Pasteur de Lille, Laboratory of Genetic Toxicology, F-59019, Lille, France.,Servier Group, F-45520, Gidy, France.,EA 4483, University of Lille 2, F-59000, Lille, France
| | - V Paget
- Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), IRCM, Laboratory of Experimental Cancerology (LCE), F-92265, Fontenay-aux-Roses, France
| | - D Chevalier
- EA 4483, University of Lille 2, F-59000, Lille, France
| | - E Lorge
- Servier Group, F-45520, Gidy, France
| | - N Claude
- Servier Group, F-45520, Gidy, France
| | - H A Girard
- Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), LIST, Diamond Sensors Laboratory, F-91191, Gif-sur-Yvette, France
| | - J C Arnault
- Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), LIST, Diamond Sensors Laboratory, F-91191, Gif-sur-Yvette, France
| | - S Chevillard
- Commissariat à l'Energie Atomique et aux Energies Renouvelables (CEA), IRCM, Laboratory of Experimental Cancerology (LCE), F-92265, Fontenay-aux-Roses, France
| | - F Nesslany
- Institut Pasteur de Lille, Laboratory of Genetic Toxicology, F-59019, Lille, France.,EA 4483, University of Lille 2, F-59000, Lille, France
| |
Collapse
|
24
|
Mortuaire G, Camous D, Vandenhende-Szymanski C, Dubrulle F, Chevalier D. Local extension staging of sinonasal tumours: retrospective comparison between CT/MRI assessment and pathological findings. Clin Otolaryngol 2017; 42:988-993. [DOI: 10.1111/coa.12827] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/05/2017] [Indexed: 12/13/2022]
Affiliation(s)
- G. Mortuaire
- Otorhinolaryngology - Head and Neck Surgery Department; University Hospital; Lille France
- Lille Inflammation Research International Center -Inserm U995; Université de Lille; Lille France
| | - D. Camous
- Otorhinolaryngology - Head and Neck Surgery Department; University Hospital; Lille France
| | - C. Vandenhende-Szymanski
- Otorhinolaryngology - Head and Neck Surgery Department; University Hospital; Lille France
- Lille Inflammation Research International Center -Inserm U995; Université de Lille; Lille France
| | - F. Dubrulle
- Department of Imaging; University Hospital; Lille France
| | - D. Chevalier
- Otorhinolaryngology - Head and Neck Surgery Department; University Hospital; Lille France
| |
Collapse
|
25
|
Gengler I, Carpentier L, Pasquesoone X, Chevalier D, Mortuaire G. Predictors of unanticipated admission within 30 days of outpatient sinonasal surgery. Rhinology 2017. [DOI: 10.4193/rhin16.251] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
26
|
Henoun Loukili N, Lemaitre N, Guery B, Gaillot O, Chevalier D, Mortuaire G. Is a chlorine dioxide wiping procedure suitable for the high-level disinfection of nasendoscopes? J Infect Prev 2016; 18:78-83. [PMID: 28989509 DOI: 10.1177/1757177416679879] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Accepted: 10/18/2016] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Nasendoscopes are widely used in the outpatient ENT setting. Their reprocessing requires high-level disinfection (HLD). Recently, a wiping procedure using chlorine dioxide (ClO2) has been proposed as an alternative to HLD traditional procedures. OBJECTIVE To assess the effectiveness of the HLD wiping procedure versus soaking procedure on a contaminated nasendoscope. METHOD A nasendoscope was contaminated with four strains of bacteria and Bacillus subtilis spores. After HLD either with the wiping procedure or with the soaking procedure (PA), the reduction of the initial contamination was determined. FINDINGS The wiping procedure with ClO2 displayed more than 5 log reduction for vegetative bacteria after 30 s contact time (CT) and 4 log reduction on B. subtilis spores after 2 min CT. The soaking procedure with PA displayed similar results on planktonic bacteria after 10 min CT but the log reduction of B. subtilis remained below 4. CONCLUSION The ClO2 wiping procedure showed bactericidal and sporicidal efficacy on a contaminated nasendoscope in a shorter time compared to the PA soaking procedure. Thus, ClO2 wiping procedure might be considered as an alternative to the traditional HLD procedure for nasendoscopes.
Collapse
Affiliation(s)
| | - Nadine Lemaitre
- Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | - Benoit Guery
- Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | - Olivier Gaillot
- Centre Hospitalier Regional Universitaire de Lille, Lille, France
| | | | | |
Collapse
|
27
|
Coche-Dequéant B, Cordoba A, Comte P, Lacornerie T, Cheval V, Escande A, Chevalier D, Julieron M, Lartigau É, Mirabel X. Mise en place de la curiethérapie à débit pulsé dans le traitement des carcinomes de la sphère ORL et stomatologique : à propos de 79cas. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.08.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
28
|
Mortuaire G, Leroy X, Vandenhende-Szymanski C, Chevalier D, Thisse AS. Comparison of endoscopic and external resections for sinonasal instestinal-type adenocarcinoma. Eur Arch Otorhinolaryngol 2016; 273:4343-4350. [PMID: 27363404 DOI: 10.1007/s00405-016-4181-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 06/25/2016] [Indexed: 10/21/2022]
Abstract
Endoscopic sinus surgery (ESS) is considered as a valid option in the management of nasal adenocarcinoma (ADC). Comparative studies with open approaches are still required. A monocentric retrospective study was carried out from May 2002 to December 2013, including 43 patients with intestinal-type adenocarcinoma of the ethmoid sinus. Non-resectable tumours or recurrences were excluded. Before 2008, open approach with lateral rhinotomy (LR) was performed as the gold standard of treatment. From 2008, ESS was systematically used as a first-line option as long as a complete resection was achievable. Adjuvant radiation therapy was delivered (RT) for all the patients. LR and ESS were performed in, respectively, 23 and 20 patients. The two groups were comparable in terms of age, occupational dust exposure, histopathological subtypes, and T stage based on the pathological assessment of the specimen (10 pT2, 26 pT3, 2 pT4a, and 5 pT4b). The tumour origin was mainly located in the olfactory cleft with the involvement of the cribriform plate in 60 % of patients. No major complication was observed in ESS group with a reduced hospital stay (5.6 vs 7.6 days). The disease-free survival was not different between LR and ESS groups over a mean follow-up period of 6.6 years. Even for local advanced stages with skull base involvement, we confirm the reliability and the advantages of ESS in terms of oncological outcomes and morbidity. We advocate complete excision of the olfactory cleft to ensure an appropriate control of the tumoral origin.
Collapse
Affiliation(s)
- Geoffrey Mortuaire
- Otorhinolaryngology-Head and Neck Surgery Department, University Hospital, Lille, France. .,Université de Lille 2, Lille, France. .,Service d'ORL de chirurgie cervico-faciale, Hôpital Huriez CHRU Lille, Lille, 59000, France.
| | - Xavier Leroy
- Université de Lille 2, Lille, France.,Pathology Department, University Hospital, Lille, France
| | | | - Dominique Chevalier
- Otorhinolaryngology-Head and Neck Surgery Department, University Hospital, Lille, France.,Université de Lille 2, Lille, France
| | - Anne-Sophie Thisse
- Otorhinolaryngology-Head and Neck Surgery Department, University Hospital, Lille, France
| |
Collapse
|
29
|
Charbonnier Q, Thisse AS, Sleghem L, Mouawad F, Chevalier D, Page C, Mortuaire G. Oncologic outcomes of patients with positive margins after laser cordectomy for T1 and T2 glottic squamous cell carcinoma. Head Neck 2016; 38:1804-1809. [PMID: 27248845 DOI: 10.1002/hed.24518] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Revised: 03/08/2016] [Accepted: 05/05/2016] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND The oncologic impact of surgical margins after transoral laser microsurgery (TLM) for T1 and T2 glottic carcinoma is controversial. The purpose of this study was to assess the prognostic value of margin status in terms of local control. METHODS Records of 266 patients treated from 1990 to 2013 were evaluated. Patients with previous cordectomy or without preoperative CT scan were excluded from the study. RESULTS A total 110 patients (85 T1a, 8 T1b, and 17 T2) were enrolled. A local recurrence was observed in 23 patients. Five-year disease-free survival was significantly impaired in patients with positive margins (p = .009) and in patients with deep involvement of the vocal muscle (p = .004). CONCLUSION The present study shows that invaded margin is a factor of poor local control even though laser vaporization was systematically applied after resection. In case of deep vocal fold involvement, TLM should be extended beyond the vocal muscle to improve local control. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1804-1809, 2016.
Collapse
Affiliation(s)
- Quentin Charbonnier
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Lille, France
| | - Anne-Sophie Thisse
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Lille, France
| | - Laurent Sleghem
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Lille, France
| | - François Mouawad
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Lille, France.,Institute for Cancer Research of Lille- Inserm U837, Université de Lille, Lille, France
| | - Dominique Chevalier
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Lille, France.,Institute for Cancer Research of Lille- Inserm U837, Université de Lille, Lille, France
| | - Cyril Page
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Amiens, France
| | - Geoffrey Mortuaire
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital, Lille, France.,Lille Inflammation Research International Center -Inserm U995, Université de Lille, Lille, France
| |
Collapse
|
30
|
Rysman B, Mouawad F, Gros A, Lansiaux A, Chevalier D, Meignan S. Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas. Head Neck 2016; 38 Suppl 1:E2412-8. [PMID: 26835877 DOI: 10.1002/hed.24367] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2015] [Revised: 10/01/2015] [Accepted: 11/25/2015] [Indexed: 11/06/2022] Open
Abstract
Human epidermal growth factor receptor 3 (HER3) is a member of the human epidermal growth factor receptor (HER) family. The main characteristic of HER3 is that it does not possess tyrosine kinase activity, unlike other HERs. The role of HER3 in tumorigenesis has now been recognized, particularly in head and neck squamous cell carcinomas (HNSCCs). Despite conflicting studies, HER3 was found to be overexpressed in HNSCC samples, and correlates with disease progression and poor survival, especially when it is coexpressed with other HERs. HER3 is a significant factor in HNSCC treatment resistance. Indeed, HER3 is a major mechanism described for cetuximab resistance because of modification of epidermal growth factor receptor (EGFR) internalization and by phosphotidylinositol-3-kinase (PI3K)/AKT signaling pathway activation. HER3 also affects resistance to tyrosine kinase inhibitors (TKIs) and thereby promotes treatment escape and radiotherapy resistance by activation of the survival signaling pathway. To counteract this, pharmacologic inhibitors of HER3 are currently in development and could significantly improve HNSCC treatment. © 2016 Wiley Periodicals, Inc. Head Neck 38: E2412-E2418, 2016.
Collapse
Affiliation(s)
- Bénédicte Rysman
- ENT and Head and Neck Surgery Department, Huriez Hospital, University of Lille, Lille, France.,Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, Inserm U908, IRCL, Lille, France
| | - François Mouawad
- ENT and Head and Neck Surgery Department, Huriez Hospital, University of Lille, Lille, France.,Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, Inserm U908, IRCL, Lille, France
| | - Abigaëlle Gros
- Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, Inserm U908, IRCL, Lille, France
| | - Amélie Lansiaux
- Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, Inserm U908, IRCL, Lille, France
| | - Dominique Chevalier
- ENT and Head and Neck Surgery Department, Huriez Hospital, University of Lille, Lille, France
| | - Samuel Meignan
- Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, Inserm U908, IRCL, Lille, France
| |
Collapse
|
31
|
Vandenhende-Szymanski C, Hochet B, Chevalier D, Mortuaire G. Olfactory cleft opacity and CT score are predictive factors of smell recovery after surgery in nasal polyposis. Rhinology 2015; 53:29-34. [PMID: 25756075 DOI: 10.4193/rhino14.160] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVES To assess subjective improvement of olfactory function following endoscopic sinus surgery (ESS) in chronic rhinosinusitis associated with nasal polyps (CRSwNP) and to analyse factors of recovery with the European Test of Olfactory Capabilities (ETOC). METHODS We carried out a prospective study of 30 patients with CRSwNP from November 2011 to April 2013. The ETOC was filled the day before surgery and in the short term follow-up. Sixteen suprathreshold odorants with a detection task and a forced choice verbal identification task were tested. RESULTS The mean composite score (MCS) improved at 3 and 6 months. The preoperative MCS was correlated to the Lund-Mackay score and to the olfactory cleft opacification on preoperative computed tomography (CT) scan. Multivariate linear regression modelling of patients with preoperative anosmia showed that the olfactory recovery at 3 months was predicted by the preoperative Lund-Mackay score and the age, and at 6 months by the preoperative Lund-Mackay score. CONCLUSION With a convenient psychophysical test, we showed that olfactory cleft opacification and CT scan score could be predictive factors of olfaction disorder severity and improvement after ESS in CRSwNP. These results need to be strengthened in the long term with a larger panel of patients.
Collapse
|
32
|
Cuny F, Babin E, Lacau-Saint-Guily J, Baujat B, Bensadoun R, Bozec A, Chevalier D, Choussy O, Deneuve S, Fakhry N, Guigay J, Makeieff M, Merol JC, Mouawad F, Pavillet J, Rebiere C, Righini C, Sostras MC, Tournaille M, Vergez S. French Society of ENT (SFORL) guidelines for care pathway organization in head and neck oncology (short version). Early management of head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2015; 132:205-8. [PMID: 26183548 DOI: 10.1016/j.anorl.2015.06.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Early management in oncology is based on coordination and high-quality exchange between the various health-care partners. The present guidelines are based on a literature search with levels of evidence. Treatment waiting time can be optimized by performing assessment as early as possible (Expert opinion), to limit the interval (ideally, less than 4 weeks) between first consultation and data collection. In the first specialist consultation, diagnostic work-up should be scheduled and the data required for management should be determined (Grade B). Work-up may be conducted on a day-care basis or with conventional admission (Expert opinion). The patient's medico-social context should be taken into account from the outset, with social work involvement whenever necessary (Expert opinion). Pain and nutritional management should be planned for (Grade A) and realistic therapeutic education be provided (Expert opinion). Community-hospital teamwork for supportive care should be optimized (Expert opinion). Management should be early and multidisciplinary, to shorten delay between diagnosis and treatment initiation.
Collapse
Affiliation(s)
- F Cuny
- Inserm U1086 cancers et prévention, service d'ORL et chirurgie cervico-faciale, CHU, avenue de la Côte-de-Nacre, 14000 Caen, France.
| | - E Babin
- Inserm U1086 cancers et prévention, service d'ORL et chirurgie cervico-faciale, CHU, avenue de la Côte-de-Nacre, 14000 Caen, France
| | | | - B Baujat
- Service d'ORL, hôpital Tenon, 4, rue de la Chine, 75018 Paris, France
| | - R Bensadoun
- Service de radiothérapie, centre Antoine-Lacassagne, 33, avenue Valombrose, 06100 Nice, France
| | - A Bozec
- Service d'ORL et chirurgie cervico-faciale, centre Antoine-Lacassagne, 33, avenue Valombrose, 06100 Nice, France
| | - D Chevalier
- Service d'ORL et chirurgie cervico-faciale, hôpital Claude-Huriez, CHRU, rue Michel Polonovski, 59037 Lille cedex, France
| | - O Choussy
- Service d'ORL et chirurgie cervico-faciale, hôpital Charles-Nicolle, 1, rue de Germont, 76000 Rouen, France
| | - S Deneuve
- Service d'ORL et chirurgie cervico-faciale, CRLCC centre Léon-Bérard, 28, promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France
| | - N Fakhry
- Service d'ORL et de chirurgie cervico-faciale, hôpital de la Conception, CHU, 147, boulevard Baille, 13005 Marseille, France
| | - J Guigay
- Unité de cancérologie médicale en cancérologie cervico-faciale, centre Antoine-Lacassagne, 33, avenue Valombrose, 06100 Nice, France
| | - M Makeieff
- Service d'ORL et chirurgie cervico-faciale, hopital Robert-Debré, CHU, avenue du Général-Koenig, 51100 Reims, France
| | - J-C Merol
- Service d'ORL et chirurgie cervico-faciale, hopital Robert-Debré, CHU, avenue du Général-Koenig, 51100 Reims, France
| | - F Mouawad
- Service d'ORL et chirurgie cervico-faciale, hôpital Claude-Huriez, CHRU, rue Michel Polonovski, 59037 Lille cedex, France
| | - J Pavillet
- Service d'oncologie médicale, CHU de Grenoble, avenue Maquis-du-Grésivaudan, 38700 La Tronche, France
| | - C Rebiere
- Service social, CHU, avenue de la Côte-de-Nacre, 14000 Caen, France
| | - C Righini
- Clinique universitaire d'ORL, pôle TCCR, CHU de Grenoble Site Nord, Pavillon Dauphiné, 38043 Grenoble cedex, France
| | - M-C Sostras
- Service social, hôpital Tenon, 4, rue de la Chine, 75018 Paris, France
| | - M Tournaille
- Service social, CLCC François-Baclesse, avenue du Général-Harris, 14000 Caen, France
| | - S Vergez
- Service d'ORL et chirurgie cervico-faciale, pôle voies respiratoires, hôpital Larrey, 24, chemin de Pouvourville, 31400 Toulouse, France
| | | |
Collapse
|
33
|
Jordan A, El Haloui O, Breaud J, Chevalier D, Antomarchi J, Bongain A, Boucoiran I, Delotte J. Formation des internes de gynécologie obstétrique : évaluation d’un programme pédagogique intégrant cours théoriques et sessions pratiques sur simulateurs. ACTA ACUST UNITED AC 2015. [DOI: 10.1016/j.gyobfe.2015.06.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
Deneuve S, Babin E, Lacau-St-Guily J, Baujat B, Bensadoun RJ, Bozec A, Chevalier D, Choussy O, Cuny F, Fakhry N, Guigay J, Makeieff M, Merol JC, Mouawad F, Pavillet J, Rebiere C, Righini CA, Sostras MC, Tournaille M, Vergez S. Guidelines (short version) of the French Otorhinolaryngology - Head and Neck Surgery Society (SFORL) on patient pathway organization in ENT: The therapeutic decision-making process. Eur Ann Otorhinolaryngol Head Neck Dis 2015; 132:213-5. [PMID: 26139415 DOI: 10.1016/j.anorl.2015.06.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVES The authors present the guidelines of the French Otorhinolaryngology - Head and Neck Surgery Society (SFORL) for patient pathway organization in head and neck cancer, and in particular for multidisciplinary team meetings. The present article concerns the therapeutic decision-making process. METHODS A multidisciplinary work group was entrusted with a review of the scientific literature on the above topic. Guidelines were drawn up, based on the articles retrieved and the group members' individual experience. They were then read over by an editorial group independent of the work group. The final version was established in a coordination meeting. The guidelines were graded as A, B, C or expert opinion, by decreasing level of evidence. RESULTS It is recommended that: an organ specialist should contribute to all multidisciplinary meetings on head and neck cancer; all members of the multidisciplinary meeting should have specific knowledge in head and neck cancer; any referring physician who does not follow the multidisciplinary meeting's advice should justify that decision; there should be sufficient time to prepare, discuss and sum up the cases dealt with in the multidisciplinary team meeting.
Collapse
Affiliation(s)
- S Deneuve
- Département de chirurgie oncologique, centre de lutte contre le cancer Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.
| | - E Babin
- Service d'ORL, CHU, avenue de la Côte-de-Nacre, 14000 Caen, France
| | - J Lacau-St-Guily
- Service d'ORL, hôpital Tenon, 4, rue de la Chine, 75018 Paris, France
| | - B Baujat
- Service d'ORL, hôpital Tenon, 4, rue de la Chine, 75018 Paris, France
| | - R-J Bensadoun
- Service d'oncologie et de radiothérapie, centre de Haute Énergie, 10, boulevard Pasteur, 06000 Nice, France
| | - A Bozec
- Service d'ORL, institut universitaire de la face et du cou, 31, avenue Valombrose, 06100 Nice, France
| | - D Chevalier
- Service d'ORL, hôpital Claude-Huriez, rue Michel Polonovski, 59037 Lille cedex, France
| | - O Choussy
- Service d'ORL, hôpital Charles-Nicolle, 1, rue de Germont, 76000 Rouen, France
| | - F Cuny
- Service d'ORL, CHU, avenue de la Côte-de-Nacre, 14000 Caen, France
| | - N Fakhry
- Service d'ORL et de chirurgie cervico-faciale, hôpital de la Conception, CHU, 147, boulevard Baille, 13005 Marseille, France
| | - J Guigay
- Service d'oncologie médicale, institut universitaire de la face et du cou, 31, avenue Valombrose, 06100 Nice, France
| | - M Makeieff
- Service d'ORL, hopital Robert-Debré, avenue du Général-Koenig, 51100 Reims, France
| | - J-C Merol
- Service d'ORL, hopital Robert-Debré, avenue du Général-Koenig, 51100 Reims, France
| | - F Mouawad
- Service d'ORL, hôpital Claude-Huriez, rue Michel Polonovski, 59037 Lille cedex, France
| | - J Pavillet
- Service d'oncologue médicale, CHU, 38043 Grenoble, France
| | - C Rebiere
- Service social, CHU, 14000 Caen, France
| | - C-A Righini
- Service d'ORL, hôpital Nord Michalon, BP 217, 38043 Grenoble cedex, France
| | - M-C Sostras
- Service social, hôpital Tenon, 4, rue de la Chine, 75018 Paris, France
| | - M Tournaille
- Service social, CLCC François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France
| | - S Vergez
- Service d'ORL, hôpital Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex 9, France
| |
Collapse
|
35
|
David V, Leger P, You F, Chevalier D, Loppinet V. 245 Identifying needs in education for children aged 7–8 y and their parents. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30420-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Leger P, David V, Le Rhun A, Chevalier D. 290 Dietary forcing and conflicts during meals for children suffering from cystic fibrosis: The psychologist's point of view. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30464-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Kerbrat M, Fretay R, Chevalier D, You F, Chiffoleau M, Hubault A, Matras C, Berhault I, Jousseaume M, L'Abbé M, Pingon C, Quillevere M, Paul S, Sery K, Idres M. 272 A proposal for specific monitoring sheets for patients taking ivacaftor. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30446-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
38
|
Mortuaire G, Leroy X, Gengler I, Chevalier D, Prin L, Picry A. Histopathological classification of refractory chronic rhinosinusitis with nasal polyps. Histol Histopathol 2015; 30:1447-54. [PMID: 25986951 DOI: 10.14670/hh-11-632] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To delineate the histopathological characteristics of nasal mucosa in refractory chronic rhinosinusitis with nasal polyps (CRSwNP) in order to demonstrate subtypes of nasal polyps and their potential relation with lower airway comorbidity. STUDY DESIGN Clinical- and pathological-based cross-sectional study Methods: Nasal polyp specimens were prospectively collected from patients with refractory CRSwNP referred to our institution for endoscopic sinus surgery. Oral and topical steroids were stopped 1 month before surgery. The pathological analysis was conducted by 2 independent reviewers with light microscopy on Hematoxylin-Eosin-Saffron stained slides. Each observer fulfilled a standardized protocol with cell count and stromal characterization on the most representative field. Mean grading scores were established. Morphological aspects were compared with the cell distribution and the clinical conditions. RESULTS Among 36 patients, three subtypes of nasal polyps were depicted: eosinophilic edematous (64%), fibrous (9%) and intermediate with mixed edematous and collagen stromal structure (27%). Basement membrane thickening and seromucous gland hyperplasia were observed in the fibrosis sub-type (p<0.03). Eosinophilic mucosal infiltrate was significantly increased (p=0.026) in patients with concomitant pulmonary disease (n=21). Nasal polyp distribution was not influenced by asthma, allergy, previous surgery and smoking. CONCLUSION Our 3-subtype classification of refractory CRSwNP in Caucasian population shows a predominant edematous structure whatever the clinical conditions may have been. Eosinophilia as a major factor of adaptive immune response in nasal inflammation is a feature of concomitant pulmonary disease. Further studies concerning mucosal remodelling and outcome assessment after sinus surgery are required to evaluate the impact of our classification on a daily basis.
Collapse
Affiliation(s)
- G Mortuaire
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital of Lille, France and EA 2686- French Eosinophil Network, University Hospital of Lille, Lille, France.
| | - X Leroy
- Pathology Department, University Hospital of Lille, France. Lille
| | - I Gengler
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital of Lille, Lille, France
| | - D Chevalier
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital of Lille, Lille, France
| | - L Prin
- EA 2686- French Eosinophil Network, University Hospital of Lille, Lille, France
| | - A Picry
- Otorhinolaryngology - Head and Neck Surgery Department, University Hospital of Lille, Lille, France
| |
Collapse
|
39
|
Mortuaire G, Gengler I, Vandenhende-Szymanski C, Delbeke M, Gatault S, Chevalier D, Prin L, Capron M. Immune profile modulation of blood and mucosal eosinophils in nasal polyposis with concomitant asthma. Ann Allergy Asthma Immunol 2015; 114:299-307.e2. [PMID: 25704963 DOI: 10.1016/j.anai.2015.01.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Revised: 12/01/2014] [Accepted: 01/23/2015] [Indexed: 01/21/2023]
Abstract
BACKGROUND Chronic rhinosinusitis with nasal polyps (CRSwNP) is frequently associated with asthma. Mucosal eosinophil (EO) infiltrate has been found to correlate with asthma and disease severity but not necessarily in every patient. Other multifactorial immune processes are required to determine disease endotypes and response to treatment. OBJECTIVE To evaluate EO immunomodulation for migration and survival in accordance with inflammatory protein profiles and asthmatic status in CRSwNP. METHODS Ninety-three patients (47 with asthma) with CRSwNP were included. Each patient was staged clinically according to symptom severity and polyp size. Nasal secretions were collected to establish a cytokine profile. The EOs were purified from blood samples and nasal polyps to delineate specific immunophenotypes by flow cytometry and determine in vitro EO survival in relation to asthmatic status. RESULTS The CRSwNP in patients with asthma was characterized by eosinophilia and a high level of interleukin (IL)-5 in nasal secretions. Although EOs exhibited activation profiles after mucosal migration, there was relative down-expression of IL-5 receptor-α (IL-5Rα) on nasal EOs in patients with asthma. The EO culture with IL-5 and IL-9 showed an antiapoptotic effect in patients with asthma through IL-5Rα modulation. CONCLUSION Mucosal eosinophilia seems to be induced by EO nasal trapping through modulation of adhesion receptors. In patients with asthma, EO involvement is enhanced by the antiapoptotic synergistic action of T-helper cell type 2 cytokines on IL-5Rα expression. This study shows for the first time that IL-9 is involved in EO homeostasis in CRSwNP and could explain the low benefit of anti-IL-5 therapy for some patients with asthma and nasal polyposis.
Collapse
Affiliation(s)
- Geoffrey Mortuaire
- INSERM U995, Université de Lille, Lille, France; EA 2686, Université de Lille, Lille, France; Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital, Lille, France; French Eosinophil Network, University Hospital, Lille, France.
| | - Isabelle Gengler
- INSERM U995, Université de Lille, Lille, France; Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital, Lille, France
| | - Claire Vandenhende-Szymanski
- INSERM U995, Université de Lille, Lille, France; Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital, Lille, France
| | | | | | - Dominique Chevalier
- Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital, Lille, France
| | - Lionel Prin
- EA 2686, Université de Lille, Lille, France; French Eosinophil Network, University Hospital, Lille, France
| | | |
Collapse
|
40
|
Laccourreye O, Chabolle F, Fraysse B, Chevalier D, Martin C. At the crossroads. Eur Ann Otorhinolaryngol Head Neck Dis 2015; 132:1-2. [DOI: 10.1016/j.anorl.2014.11.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Accepted: 11/12/2014] [Indexed: 11/28/2022]
|
41
|
Vandenhende-Szymanski C, Hochet B, Chevalier D, Mortuaire G. Olfactory cleft opacity and CT score are predictive factors of smell recovery after surgery in nasal polyposis. Rhinology 2015. [DOI: 10.4193/rhin14.160] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
42
|
Boute P, Page C, Biet A, Cuvelier P, Strunski V, Chevalier D. Epidemiology, prognosis and treatment of simultaneous squamous cell carcinomas of the oral cavity and hypopharynx. Eur Ann Otorhinolaryngol Head Neck Dis 2014; 131:283-7. [PMID: 25288121 DOI: 10.1016/j.anorl.2013.10.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2013] [Accepted: 10/27/2013] [Indexed: 11/29/2022]
Abstract
OBJECTIVE The study was designed to assess the prevalence, management and survival of patients with simultaneous squamous cell carcinomas of the oral cavity and hypopharynx (OC/HP). MATERIAL AND METHODS A multicenter, retrospective study (2 university hospitals) was conducted between 2003 and 2007 on a series of 96 patients with simultaneous squamous cell cancers of the OC/HP. RESULTS A total of 88 men and 8 women were included in the study: 81 patients presented double sites, 14 presented triple sites and one presented quadruple sites. The tumour sites most frequently observed were: hypopharynx in 61% of cases (involving the pyriform sinus in 42% of cases) and the oropharynx in 59% of cases (involving the palatine tonsil in 30% of cases). Upper aerodigestive tract endoscopy under general anaesthesia revealed a simultaneous lesion not suspected on clinical examination in 45% of patients: the site discovered on endoscopy was hypopharyngeal in 2 out of 3 cases; the tumour was classified T1 or T2 in 95.5% of cases. Patients treated simultaneously for all sites had a better prognosis than patients in whom each tumour was treated separately. The 5-year specific survival was 34% and the 5-year overall survival was 28%. CONCLUSION The prevalence of simultaneous squamous cell carcinomas of the oral cavity and hypopharynx ranges between 1 to 7.4% in the literature and was 4.6% in the present series. A common treatment strategy for each of the patient's tumours appears to be superior to the current theoretical approach that consists of considering each tumour separately.
Collapse
Affiliation(s)
- P Boute
- Service d'ORL et chirurgie cervico-faciale, CHU d'Amiens, Centre Hospitalier Nord, place Victor-Pauchet, 80054 Amiens cedex, France.
| | - C Page
- Service d'ORL et chirurgie cervico-faciale, CHU d'Amiens, Centre Hospitalier Nord, place Victor-Pauchet, 80054 Amiens cedex, France
| | - A Biet
- Service d'ORL et chirurgie cervico-faciale, CHU d'Amiens, Centre Hospitalier Nord, place Victor-Pauchet, 80054 Amiens cedex, France
| | - P Cuvelier
- Service d'ORL et chirurgie cervico-faciale, CHU d'Amiens, Centre Hospitalier Nord, place Victor-Pauchet, 80054 Amiens cedex, France
| | - V Strunski
- Service d'ORL et chirurgie cervico-faciale, CHU d'Amiens, Centre Hospitalier Nord, place Victor-Pauchet, 80054 Amiens cedex, France
| | - D Chevalier
- Service d'ORL et chirurgie cervico-faciale, CHRU, 2, avenue Oscar-Lambret, 59037 Lille cedex, France
| |
Collapse
|
43
|
Succo G, Peretti G, Piazza C, Remacle M, Eckel HE, Chevalier D, Simo R, Hantzakos AG, Rizzotto G, Lucioni M, Crosetti E, Antonelli AR. Open partial horizontal laryngectomies: a proposal for classification by the working committee on nomenclature of the European Laryngological Society. Eur Arch Otorhinolaryngol 2014; 271:2489-96. [DOI: 10.1007/s00405-014-3024-4] [Citation(s) in RCA: 109] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Accepted: 03/20/2014] [Indexed: 11/30/2022]
|
44
|
Simo R, Bradley P, Chevalier D, Dikkers F, Eckel H, Matar N, Peretti G, Piazza C, Remacle M, Quer M. European Laryngological Society: ELS recommendations for the follow-up of patients treated for laryngeal cancer. Eur Arch Otorhinolaryngol 2014; 271:2469-79. [PMID: 24609733 DOI: 10.1007/s00405-014-2966-x] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2011] [Accepted: 02/13/2014] [Indexed: 11/30/2022]
Abstract
It is accepted that the follow-up of patients who had treatment for laryngeal cancer is a fundamental part of their care. The reasons of post-treatment follow-up include evaluation of treatment response, early identification of recurrence, early detection of new primary tumours, monitoring and management of complications, optimisation of rehabilitation, promotion smoking and excessive alcohol cessation, provision of support to patients and their families, patient counselling and education. Controversies exist in how these aims are achieved. Increasing efforts are being made to rationalise the structure and timing of head and neck cancer follow-up clinics. The aim of this document is to analyse the current evidence for the need to follow up patients who have been treated for LC and provide an up to date, evidence-based statement which is meaningful and applicable to all European Health Care Systems. A working group of the Head and Neck Cancer Committee of the ELS was constituted in 2009. A review of the current published literature on the management and follow-up of laryngeal cancer was undertaken and statements are made based on critical appraisal of the literature and best current evidence. Category recommendations were based on the Oxford Centre for Evidence-Based Medicine. Statements include: length, frequency, setting, type of health professional, clinical assessment, screening investigations, patient's education, second primary tumours, and mode of treatment considerations including radiotherapy, chemo-radiation therapy, transoral surgery and open surgery. It also addresses specific recommendations regarding patients with persistent pain, new imaging techniques, tumour markers and narrow band imaging.
Collapse
Affiliation(s)
- Ricard Simo
- Department of Otorhinolaryngology Head and Neck Surgery, Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
OBJECTIVE To assess the safety and efficacy of submucosal radiofrequency (RF) treatment for hereditary hemorrhagic telangiectasia (HHT) with mild or moderate epistaxis. METHODOLOGY We carried out a prospective pilot study of 16 consecutive patients with HHT-related epistaxis from June 2010 to April 2012. Under local anesthesia, RF was applied to one or both sides of the nose from the columella beneath the septal mucosal (50 joules per puncture). Patients were sent a questionnaire at least six months after the procedure. RESULTS RF under local anesthesia was well tolerated, according to visual analog scale scores. Neither crusting nor pain was reported one week after the intervention. The frequency of epistaxis per day and per month was significantly lower after RF. The duration of bleeding also decreased from more than 10 minutes to less than 5 minutes in two thirds of patients. Thirteen of the 16 patients were satisfied with the technique and would request it for subsequent procedures to treat repeated bleeding. CONCLUSION Submucosal RF treatment for HHT is a safe, well tolerated procedure with significant efficacy in the short term. It should be considered as an alternative technique for managing HHT-related epistaxis, although long-term results remain to be evaluated.
Collapse
|
46
|
Vannimenus-Hayem C, Scherpereel A, Chevalier D, Lefebvre G, Dansin E, Lafitte J, Pasquesoone X, Lefebvre J, Rolland B, Pavy-Bricout H. Suivi des consommations de tabac et d’alcool après un premier cancer du poumon ou des voies aériennes supérieures : état des lieux à la fin des inclusions de l’étude Altak. Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2013.10.388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
47
|
Mortuaire G, Boute O, Hatron P, Chevalier D. Pilot study of submucosal radiofrequency for epistaxis in hereditary hemorrhagic telangiectasia. Rhinology 2013; 51:355-60. [DOI: 10.4193/rhino13.027] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Objective: To assess the safety and efficacy of submucosal radiofrequency (RF) treatment for hereditary hemorrhagic telangiectasia (HHT) with mild or moderate epistaxis. Methodology: We carried out a prospective pilot study of 16 consecutive patients with HHT-related epistaxis from June 2010 to April 2012. Under local anesthesia, RF was applied to one or both sides of the nose from the columella beneath the septal mucosal (50 joules per puncture). Patients were sent a questionnaire at least six months after the procedure. Results: RF under local anesthesia was well tolerated, according to visual analog scale scores. Neither crusting nor pain was reported one week after the intervention. The frequency of epistaxis per day and per month was significantly lower after RF. The duration of bleeding also decreased from more than 10 minutes to less than 5 minutes in two thirds of patients. Thirteen of the 16 patients were satisfied with the technique and would request it for subsequent procedures to treat repeated bleeding. Conclusion: Submucosal RF treatment for HHT is a safe, well tolerated procedure with significant efficacy in the short term. It should be considered as an alternative technique for managing HHT-related epistaxis, although long-term results remain to be evaluated.
Collapse
|
48
|
Mirghani H, Mortuaire G, Armas GL, Hartl D, Aupérin A, El Bedoui S, Chevalier D, Lefebvre JL. Sinonasal cancer: Analysis of oncological failures in 156 consecutive cases. Head Neck 2013; 36:667-74. [DOI: 10.1002/hed.23356] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2012] [Revised: 11/22/2012] [Accepted: 04/09/2013] [Indexed: 11/07/2022] Open
Affiliation(s)
- Haïtham Mirghani
- Head and Neck Department; Institut Gustave Roussy; Villejuif France
| | - Geoffrey Mortuaire
- Otorhinolaryngology and Head and Neck Surgery Department; Huriez Hospital; University of Lille; France
| | - Gian Luca Armas
- Otorhinolaryngology and Head and Neck Surgery Department; Santa Chiara Hospital; Trento Italy
| | - Dana Hartl
- Head and Neck Department; Institut Gustave Roussy; Villejuif France
| | - Anne Aupérin
- Biostatistics and Epidemiology Department; Institut Gustave Roussy; Villejuif France
| | | | - Dominique Chevalier
- Otorhinolaryngology and Head and Neck Surgery Department; Huriez Hospital; University of Lille; France
| | | |
Collapse
|
49
|
Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E. Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study. J Clin Oncol 2013; 31:853-9. [DOI: 10.1200/jco.2012.42.3988] [Citation(s) in RCA: 298] [Impact Index Per Article: 27.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To compare the efficacy and safety of induction chemotherapy (ICT) followed by chemoradiotherapy (CRT) or bioradiotherapy (BRT) for larynx preservation (LP). Patients and Methods Previously untreated patients with stage III to IV larynx/hypopharynx squamous cell carcinoma received three cycles of ICT—docetaxel and cisplatin 75 mg/m2 each on day 1 and fluorouracil 750 mg/m2 per day on days 1 through 5. Poor responders (< 50% response) underwent salvage surgery. Responders (≥ 50% response) were randomly assigned to conventional radiotherapy (RT; 70 Gy) with concurrent cisplatin 100 mg/m2 per day on days 1, 22, and 43 of RT (arm A) or concurrent cetuximab 400 mg/m2 loading dose and 250 mg/m2 per week during RT (arm B). Primary end point was LP at 3 months. Secondary end points were larynx function preservation (LFP) and overall survival (OS) at 18 months. Results Of the 153 enrolled patients, 116 were randomly assigned after ICT (60, arm A; 56, arm B). Overall toxicity of both CRT and BRT was substantial following ICT. However, treatment compliance was higher in the BRT arm. In an intent-to-treat analysis, there was no significant difference in LP at 3 months between arms A and B (95% and 93%, respectively), LFP (87% and 82%, respectively), and OS at 18 months (92% and 89%, respectively). There were fewer local treatment failures in arm A than in arm B; salvage surgery was feasible in arm B only. Conclusion There is no evidence that one treatment was superior to the other or could improve the outcome reported with ICT followed by RT alone (French Groupe Oncologie Radiothérapie Tête et Cou [GORTEC] 2000-01 trial [Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma]). The protocol that can best compare with RT alone after ICT is still to be determined.
Collapse
Affiliation(s)
- Jean Louis Lefebvre
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Yoann Pointreau
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Frederic Rolland
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Marc Alfonsi
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Alain Baudoux
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Christian Sire
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Dominique de Raucourt
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Olivier Malard
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Marian Degardin
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Claude Tuchais
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Emmanuel Blot
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Michel Rives
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Emile Reyt
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Jean Marc Tourani
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Lionel Geoffrois
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Frederic Peyrade
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Francois Guichard
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Dominique Chevalier
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Emmanuel Babin
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Philippe Lang
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Francois Janot
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Gilles Calais
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Pascal Garaud
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| | - Etienne Bardet
- Jean Louis Lefebvre and Marian Degardin, Centre Oscar Lambret; Dominique Chevalier, Centre Hospitalier Universitaire Claude Huriez, Lille; Yoann Pointreau, Gilles Calais, and Pascal Garaud, Centre Hospitalier Universitaire Pierre Bretonneau, Tours; Frederic Rolland and Etienne Bardet, Institut de Cancerologie de l'Ouest Rene Gauducheau; Olivier Malard, Centre Hospitalier Universitaire Hotel Dieu, Nantes; Marc Alfonsi, Institut Sainte Catherine, Avignon; Christian Sire, Centre Hospitalier Bretagne Sud,
| |
Collapse
|
50
|
Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C, Laurent G, Saussez S. Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J Cancer Res Clin Oncol 2013; 139:727-37. [PMID: 23354841 DOI: 10.1007/s00432-013-1375-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2012] [Accepted: 10/22/2012] [Indexed: 01/14/2023]
Abstract
PURPOSE The present in vivo/in vitro study was undertaken in order to evaluate the importance of macrophage migration inhibitory factor (MIF) in the progression of head and neck squamous cell carcinoma (HNSCC). METHODS Tumor tissue expression (MIF immunostaining) and plasma levels (ELISA) of MIF were determined in HNSCC patients and correlated with tumor recurrence and metastasis, and overall survival. Furthermore, the impact of MIF expression on cell proliferation and anticancer drug sensitivity was examined in murine squamous carcinoma cell line SCCVII after MIF knockdown (MIF-KD). RESULTS As revealed by quantitative analysis of MIF immunostaining, tumor progression was accompanied by an increase in mean optical density (MOD) and labeling index (LI). Likewise, an elevation of MIF serum levels was noted in HNSCC patients (n = 66) versus healthy individuals (n = 16). Interestingly, comparison of laryngeal carcinoma patients on the basis of MIF tissue expression (high expression, LI ≥ 47, versus low expression, LI < 47) disclosed a significant difference between disease-free survival curves for local and nodal recurrence, and overall survival curve. In vitro, MIF knockdown in murine SCCVII cells resulted in reduced cell proliferation and a decrease in cell motility. In mice inoculated with SCCVII cells, MIF-KD tumors grew more slowly and also appeared more sensitive to chemotherapy. CONCLUSIONS Both clinical observations and experimental data suggest that MIF plays a pivotal role in the progression of HNSCC.
Collapse
Affiliation(s)
- Nadège Kindt
- Laboratory of Anatomy and Cellular Biology, Faculty of Medicine and Pharmacy, University of Mons, Pentagone 2A, 6 Ave du Champ de Mars, 7000 Mons, Belgium
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|